药物性肝损伤的潜在机制、病理特点及生物标志物

耿文静; 刘晖; 丁惠国

doi:10.3969/j.issn.1001-5256.2019.04.049

药物性肝损伤的潜在机制、病理特点及生物标志物

DOI: 10.3969/j.issn.1001-5256.2019.04.049

1. 首都医科大学附属北京佑安医院肝病消化中心
2. 首都医科大学附属北京佑安医院病理中心

基金项目:

北京市医院管理局扬帆计划(ZYLX201610)；登峰计划(DFL20151602)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1458
- HTML全文浏览量: 57
- PDF下载量: 343
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Recent advances in drug-induced liver injury: Potential mechanisms, pathological features, and biomarkers

Department of Hepatology and Gastroenterology, Beijing YouAn Hospital, Capital Medical University

Research funding:

摘要

摘要: 药物性肝损伤(DILI)是急性肝衰竭、黑盒子警告以及药物撤市的主要原因之一,也是公共卫生、医药研发以及制药行业关注的主要问题。但因缺乏特异性诊断标志物使DILI的诊断成为临床医生的一大挑战。总结了DILI研究的最新进展,包括潜在机制、病理特点、生物标志物以及体外研究方法等,希望为DILI的临床及病理诊断和判断预后等提供参考。
- 药物性肝损伤 /
- 病理过程 /
- 生物学标记 /
- 综述
Abstract: Drug-induced liver injury ( DILI) is one of the main causes of acute liver failure, black box warnings, and drug withdrawal from the market, and it is also a major concern in public health, drug research and development, and the pharmaceutical industry. However, a lack of specific diagnostic markers for DILI makes the diagnosis of this disease a major challenge for clinicians. This article summarizes the recent advances in DILI research, including potential mechanisms, pathological features, biomarkers, and in vitro methods, in order to provide a reference for clinical and pathological diagnosis and prognostic evaluation of DILI.
- drug-induced liver injury /
- pathologic processes /
- biological markers /
- review

HTML全文

参考文献(39)

[1]SGRO C, CLINARD F, OUAZIR K, et al.Incidence of druginduced hepatic injuries:A French populationbased study[J].Hepatology, 2002, 36 (2) :451-455.

[2]BJORNSSON ES, BERGMANN OM, BJORNSSON HK, et al.Incidence, presentation, and outcomes in patients with druginduced liver injury in the general population of Iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.

[3]KIM KA.Current status of liver diseases in Korea:Toxic and alcoholic liver diseases[J].Korean J Hepatol, 2009, 15 (6) :s29-s33.

[4]de ABAJO FJ, MONTERO D, MADURGA M, et al.Acute and clinically relevant drug-induced liver injury:A population based case-control study[J].Br J Clin Pharmacol, 2004, 58 (1) :71-80.

[5]RUIGO'MEZ A, BRAUER R, RODRI'GUEZ LA, et al.Ascertainment of acute liver injury in two European primary care databases[J].Eur J Clin Pharmacol, 2014, 70 (10) :1227-1235.

[6]ORTEGAALONSO A, ANDRADE RJ.Chronic liver injury induced by drugs and toxins[J].J Dig Dis, 2018, 19 (9) :514-521.

[7]HILLMAN L, GOTTFRIED M, WHITSETT M, et al.Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury[J].Am J Gastroenterol, 2016, 111 (7) :958-965.

[8]SINGH D, CHO WC, UPADHYAY G.Drug-induced liver toxicity and prevention by herbal antioxidants:An overview[J].Front Physiol, 2016, 6:363.

[9]WATKINS PB, KAPLOWITZ N, SLATTERY JT, et al.Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily:A randomized controlled trial[J].JA-MA, 2006, 296 (1) :87-93.

[10]KULLAKUBLICK GA, ANDRADE RJ, MERZ M, et al.Druginduced liver injury:Recent advances in diagnosis and risk assessment[J].Gut, 2017, 66 (6) :1154-1164.

[11]KIM SH, NAISBITT DJ.Update on advances in research on idiosyncratic drug-induced liver injury[J].Allergy Asthma Immunol Res, 2016, 8 (1) :3-11.

[12]CORSINI A, BORTOLINI M.Drug-induced liver injury:The role of drug metabolism and transport[J].J Clin Pharmacol, 2013, 53 (5) :463-474.

[13]ROTH AD, LEE MY.Idiosyncratic drug-induced liver injury (IDILI) :Potential mechanisms and predictive assays[J].Biomed Res Int, 2017, 2017 (1) :1-23.

[14]UTKARSH D, LORETZ C, LI AP.In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors:Identification of P450 activity as a potential risk factor for drug-induced liver injuries[J].Chem Biol Interact, 2016, 255:12-22.

[15]TAN XQ, YANG GQ, ZHANG L, et al.Research progress on CYP2E1 mediating toxicity by exogenous chemicals[J].China Occup Med, 2016, 43 (2) :234-236. (in Chinese) 谭孝琼, 杨光谦, 张林, 等.细胞色素P450 2E1介导外源性化合物毒性损伤研究进展[J].中国职业医学, 2016, 43 (2) :234-236.

[16]MACKAY RJ, MCENTYRE CJ, HENDERSON C, et al.Trimethylaminuria:Causes and diagnosis of a socially distressing condition[J].Clin Biochem Rev, 2011, 32 (1) :33-34.

[17]MARQUES SC, IKEDIOBI ON.The clinical application of UGT1A1pharmacogenetic testing:Gene-environment interactions[J].Hum Genomics, 2010, 4 (4) :238-249.

[18]CRETTOL S, PETROVIC N, MURRAY M.Pharmacogenetics of phase I and phase II drug metabolism[J].Curr Pharm Des, 2010, 16 (2) :204-219.

[19]KALIYAPERUMAL K, GROVE JI, DELAHAY RM, et al.Pharmacogenomics of drug-induced liver injury (DILI) :Molecular biology to clinical applications[J].J Hepatol, 2018, 69 (4) :948-957.

[20]GMEZLECHN MJ, TOLOSA L, DONATO MT.Metabolic activation and drug-induced liver injury:In vitro approaches for the safety risk assessment of new drugs[J].J Appl Toxicol, 2016, 36 (6) :752-768.

[21]BHARATHI V, RENGARAJAN RL, RADHAKRISHNAN R, et al.Effects of a medicinal plant Macrotyloma uniflorum, (Lam.) Verdc.formulation (MUF) on obesity-associated oxidative stress-induced liver injury[J].Saudi J Biol Sci, 2018, 25 (6) :1115-1121.

[22]AYALA A, MUOZ MF, ARGELLES S.Lipid peroxidation:Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal[J].Oxid Med Cell Longev, 2014, 2014 (6) :1-31.

[23]SHEHU AI, MA X, VENKATARAMANAN R.Mechanisms of drug-induced hepatotoxicity[J].Clin Liver Dis, 2017, 21 (1) :35-54.

[24]MASUBUCHI Y, SUDA C, HORIE T.Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice[J].J Hepatol, 2005, 42 (1) :110-116.

[25]ALEO MD, LUO Y, SWISS R, et al.Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump[J].Hepatology, 2014, 60 (3) :1015-1022.

[26]MOSEDALE M, WATKINS PB.Drug-induced liver injury:Advances in mechanistic understanding that will inform risk management[J].Clin Pharmacol Ther, 2017, 101 (4) :469-480.

[27]DARA L, LIU ZX, KAPLOWITZ N.Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications[J].Liver Int, 2016, 36 (2) :158-165.

[28]KLEINER DE, CHALASANI NP, LEE WM, et al.Hepatic histological findings in suspected drug-induced liver injury:Systematic evaluation and clinical associations[J].Hepatology, 2014, 59 (2) :661-670.

[29]KLEINER DE.The histopathological evaluation of drug-induced liver injury[J].Histopathology, 2017, 70 (1) :81-93.

[30]YANG RY, ZHAO XY.Significance of liver histopathological examination in diagnosis and treatment of drug-induced liver injury[J].J Clin Hepatol, 2018, 34 (6) :1172-1175. (in Chinese) 杨瑞园, 赵新颜.肝组织病理学检查在药物性肝损伤诊治中的意义[J].临床肝胆病杂志, 2018, 34 (6) :1172-1175.

[31]KHOURY T, RMEILEH AA, YOSHA L, et al.Drug induced liver injury:Review with a focus on genetic factors, tissue diagnosis, and treatment options[J].J Clin Transl Hepatol, 2015, 3 (2) :99-108.

[32]LAWAL A, ZHANG M, DITTMAR M, et al.Heme oxygenase-1protects endothelial cells from the toxicity of air pollutant chemicals[J].Toxicol Appl Pharmacol, 2015, 284 (3) :281-291.

[33]BAKHAUTDIN B, DAS D, MANDAL P, et al.Protective role of HO-1 and carbon monoxide in ethanol-induced hepatocyte cell death and liver injury in mice[J].J Hepatol, 2014, 61 (5) :1029-1037.

[34]GAO Y, CAO Z, YANG X, et al.Proteomic analysis of acetaminophen-induced hepatotoxicity and identification of heme oxygenase 1 as a potential plasma biomarker of liver injury[J].Proteomics Clin Appl, 2017, 11 (1-2) .

[35]CHURCH RJ, KULLAK-UBLICK GA, AUBRECHT J, et al.Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort[J].Hepatology, 2019, 69 (2) :760-773.

[36]ROBLES-DAZ M, MEDINA-CALIZ I, STEPHENS C, et al.Biomarkers in DILI:One more step forward[J].Front Pharmacol, 2016, 7:267.

[37]LIU XQ, WU WX, GENG XC, et al.Research progress of biomarkers of druginduced liver injury[J].Chin J New Drugs, 2018, 27 (1) :47-52. (in Chinese) 刘小茜, 吴文晓, 耿兴超, 等.药物性肝损伤生物标志物研究进展[J].中国新药杂志, 2018, 27 (1) :47-52.

[38]CHO YE, SONG BJ, AKBAR M, et al.Extracellular vesicles as potential biomarkers for alcohol-and drug-induced liver injury and their therapeutic applications[J].Pharmacol Ther, 2018, 187:180-194.

[39]BENESIC A, ROTTER I, DRAGOI D, et al.Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2018, 16 (9) :1488-1494.e5.

施引文献

资源附件(0)

访问统计